Biotech · Private company
Byondis B.V.
Track this companyFree. Adds Byondis B.V. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- (vic-)trastuzumab duocarmazinePhase 3 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Physician's choicePhase 3 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SYD985Phase 2 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerPHASE1 · WITHDRAWN · started Jul 28, 2021ClinicalTrials.gov NCT04602117 · fetched Nov 12, 2026
- SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial CarcinomaPHASE2 · COMPLETED · started May 28, 2020ClinicalTrials.gov NCT04205630 · fetched Nov 12, 2026
- SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerPHASE3 · COMPLETED · started Dec 15, 2017ClinicalTrials.gov NCT03262935 · fetched Nov 12, 2026